BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26230938)

  • 1. Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
    Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
    Bioconjug Chem; 2015 Aug; 26(8):1839-49. PubMed ID: 26230938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Group B Streptococcus Glycan-Conjugate Vaccines Using Pilus Protein GBS80 As Carrier and Antigen: Comparing Lysine and Tyrosine-directed Conjugation.
    Nilo A; Morelli L; Passalacqua I; Brogioni B; Allan M; Carboni F; Pezzicoli A; Zerbini F; Maione D; Fabbrini M; Romano MR; Hu QY; Margarit I; Berti F; Adamo R
    ACS Chem Biol; 2015 Jul; 10(7):1737-46. PubMed ID: 25906283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry.
    Nilo A; Allan M; Brogioni B; Proietti D; Cattaneo V; Crotti S; Sokup S; Zhai H; Margarit I; Berti F; Hu QY; Adamo R
    Bioconjug Chem; 2014 Dec; 25(12):2105-11. PubMed ID: 25415860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation.
    Pecetta S; Lo Surdo P; Tontini M; Proietti D; Zambonelli C; Bottomley MJ; Biagini M; Berti F; Costantino P; Romano MR;
    Vaccine; 2015 Jan; 33(2):314-20. PubMed ID: 25448110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.
    Goyette-Desjardins G; Calzas C; Shiao TC; Neubauer A; Kempker J; Roy R; Gottschalk M; Segura M
    Infect Immun; 2016 Jul; 84(7):2059-2075. PubMed ID: 27113360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines.
    Adamo R
    Acc Chem Res; 2017 May; 50(5):1270-1279. PubMed ID: 28463499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.
    Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R
    Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
    Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
    J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.
    Baraldo K; Mori E; Bartoloni A; Norelli F; Grandi G; Rappuoli R; Finco O; Del Giudice G
    Infect Immun; 2005 Sep; 73(9):5835-41. PubMed ID: 16113302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines.
    Stefanetti G; Rondini S; Lanzilao L; Saul A; MacLennan CA; Micoli F
    Vaccine; 2014 Oct; 32(46):6122-9. PubMed ID: 25192974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes.
    Madoff LC; Paoletti LC; Tai JY; Kasper DL
    J Clin Invest; 1994 Jul; 94(1):286-92. PubMed ID: 7518832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide.
    Csordas FC; Perciani CT; Darrieux M; Gonçalves VM; Cabrera-Crespo J; Takagi M; Sbrogio-Almeida ME; Leite LC; Tanizaki MM
    Vaccine; 2008 Jun; 26(23):2925-9. PubMed ID: 18440673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carrier priming effect of CRM197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM197 and diphtheria toxoid.
    Pecetta S; Tontini M; Faenzi E; Cioncada R; Proietti D; Seubert A; Nuti S; Berti F; Romano MR
    Vaccine; 2016 Apr; 34(20):2334-41. PubMed ID: 27015733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction to Exploring the Effect of Conjugation Site and Chemistry on the Immunogenicity of an anti-Group B Streptococcus Glycoconjugate Vaccine Based on GBS67 Pilus Protein and Type V Polysaccharide.
    Nilo A; Passalacqua I; Fabbrini M; Allan M; Usera A; Carboni F; Brogioni B; Pezzicoli A; Cobb J; Romano MR; Margarit I; Hu QY; Berti F; Adamo R
    Bioconjug Chem; 2015 Oct; 26(10):2167. PubMed ID: 26355285
    [No Abstract]   [Full Text] [Related]  

  • 17. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity.
    Michon F; Uitz C; Sarkar A; D'Ambra AJ; Laude-Sharp M; Moore S; Fusco PC
    Clin Vaccine Immunol; 2006 Aug; 13(8):936-43. PubMed ID: 16893995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new vaccine concept: polysaccharide conjugate vaccines].
    Moreau M
    Ann Pharm Fr; 1999 May; 57(3):223-31. PubMed ID: 10427857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential Linkage of Carbohydrate Antigens to Mimic Capsular Polysaccharides: Toward Semisynthetic Glycoconjugate Vaccine Candidates against
    Seco BMS; Xu FF; Grafmüller A; Kottari N; Pereira CL; Seeberger PH
    ACS Chem Biol; 2020 Sep; 15(9):2395-2405. PubMed ID: 32835479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.
    Micoli F; Adamo R; Costantino P
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.